查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965347

循環性腫瘤細胞市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、技術、地區和競爭對手分類，2021-2031年

Circulating Tumor Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Technology, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球循環性腫瘤細胞市場預計將從 2025 年的 70.6 億美元成長到 2031 年的 109.4 億美元，複合年成長率為 7.57%。

該市場專注於從原發腫瘤脫落並進入血液的癌細胞，這些癌細胞可作為重要的生物標記物，用於監測轉移進展和治療效果。市場成長的主要驅動力是全球癌症負擔的日益加重以及對非侵入性液態生物檢體診斷需求的成長。美國癌症協會 (ACS) 估計，到 2025 年，美國將新增 2,041,910 例癌症病例，凸顯了對有效疾病管理工具的迫切需求。此外，無需手術干預即可進行頻繁的患者評估的能力也持續推動著該行業的成長。

市場概覽
預測期 2027-2031
市場規模：2025年 70.6億美元
市場規模：2031年 109.4億美元
複合年成長率：2026-2031年 7.57%
成長最快的細分市場 試劑盒和試劑
最大的市場 北美洲

然而，市場面臨一項重大挑戰：細胞分離技術缺乏標準化。血液樣本中這些細胞的濃度極低，導致不同平台間檢測結果的一致性和可重複性難以保證。這種技術複雜性需要昂貴的設備和專門的處理方法，從而導致高昂的營運成本，限制了其在臨床上的應用以及在標準醫療體系中的報銷。

市場促進因素

微流體和晶片分離技術的進步正在改變市場格局，解決了血液樣本中細胞濃度過低這一關鍵瓶頸。這些專用平台能夠捕捉和收集無標定的循環性腫瘤細胞，從而實現以往依賴上皮標記的方法無法進行的下游分析。這些創新技術的商業性成功體現在系統應用範圍的擴大。例如，根據 Alliance News 2025 年 1 月報道，Angle 公司 2024 年全年營收成長至 290 萬英鎊，這主要得益於 Parsortix液態生物檢體系統在製藥服務和臨床領域的廣泛應用。這種向高靈敏度濃縮工具的轉變使臨床醫生能夠更精確地監測腫瘤轉移的可能性，從而直接改善患者管理策略並推動市場成長。

同時，公共和私人機構對癌症研究投入的增加，正加速液態生物檢體技術從學術研究到常規臨床實踐的轉化。各國政府和主要醫療機構認知到緊急應變，並正大力投資於大規模研究，以檢驗循環腫瘤細胞（CTC）生物標記在早期檢測和治療方案中的應用。歐盟委員會強調了這種臨床緊迫性，並在2025年12月估計，2024年歐盟成員國將新增約270萬例癌症病例，將對可擴展的診斷解決方案產生巨大需求。為此，津貼已撥款開發新的調查方法。特別是，根據GenomeWeb在2025年5月報道，奧斯陸大學醫院獲得了歐盟1360萬歐元的津貼，用於開發和檢驗針對遺傳性癌症症候群的液態生物檢體檢測方法。

市場挑戰

細胞分離技術缺乏標準化仍是全球循環性腫瘤細胞循環性腫瘤細胞(CTC) 市場成長的主要障礙。由於 CTC 在血液樣本中的濃度極低，其檢測需要複雜且高度靈敏的設備，且不同製造商的調查方法往往存在差異。這種技術上的不一致導致不同實驗室間結果的差異以及可重複性的降低，使得腫瘤科醫生難以像使用成熟的組織切片檢查那樣，可靠地將 CTC 作為重要治療決策的依據。因此，這種差異性對監管機構的檢驗和醫學界的認可構成了重大障礙。

這些技術挑戰直接導致營運成本飆升，進一步阻礙了市場擴張。分離這些稀有細胞所需的專用設備和勞動密集型工作流程推高了每次檢測的成本，使得廣泛的保險覆蓋變得困難。美國癌症協會預測，到2025年，美國將有約618,120人死於癌症，凸顯了先進監測工具的緊迫感。然而，儘管臨床負擔如此沉重，健康保險公司和保險機構仍然不願採用昂貴且非標準化的循環腫瘤細胞（CTC）檢測，這限制了其在標準臨床實踐中的應用，並限制了市場盈利能力。

市場趨勢

人工智慧驅動的循環腫瘤細胞（CTC）自動化檢測技術的整合，從根本上改變了市場格局，克服了從數十億血細胞中識別罕見癌細胞這一長久以來的難題。先進的機器學習演算法被引入高內涵影像分析，顯著提高了檢測靈敏度，並減少了人工操作偏差造成的差異。這項技術飛躍實現了工作流程的標準化和高通量，直接解決了阻礙臨床應用的可擴展性問題。 2024年5月發表於《臨床腫瘤學雜誌》（Journal of Clinical Oncology）的一篇文章也印證了這項進展。該文章報告了一項使用自動化深度學習模型進行循環性腫瘤細胞分析的研究，其檢測準確率約為96.66%，凸顯了人工智慧在提供常規診斷應用所需可靠性方面的潛力。

同時，腫瘤檢測產業正經歷從簡單的細胞計數到分子表現型分析的關鍵轉變，並逐步發展成為能夠表徵細胞生物學特性的精準醫療。臨床醫生和研究人員不僅關注轉移負荷的評估，還致力於分析分離細胞的蛋白質組學和基因組學特徵，以識別特定的治療標靶和抗藥性機制。這種對更深入生物學洞察的追求正推動著大量投資，以支持下一代表徵工具的發展。例如，2024年6月，RareCyte成功完成了2,000萬美元的資金籌措，旨在擴展其精準生物學平台。該平台能夠實現對單一循環性腫瘤細胞的可見回收和分子分析。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球循環性腫瘤細胞市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依產品類型（試劑盒/試劑、採血管、設備或系統）
    • 按技術（CTC檢測與濃縮方法、CTC直接檢測方法、CTC分析）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美循環性腫瘤細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：循環性腫瘤細胞的歐洲市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區循環性腫瘤細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲循環性腫瘤細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲循環性腫瘤細胞市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球循環性腫瘤細胞市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • QIAGEN NV
  • Bio-Techne Corp.
  • Precision Medicine Group, LLC
  • Bio-Rad Laboratories, Inc.
  • Natera, Inc.
  • Illumina, Inc.
  • Greiner Bio-One International GmbH
  • Ikonisys Inc.
  • Creative Bioarray
  • Abnova Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 15903

The Global Circulating Tumor Cells Market to expand from USD 7.06 Billion in 2025 to USD 10.94 Billion by 2031 with a CAGR of 7.57%. The Global Circulating Tumor Cells Market is centered on cancer cells that detach from primary tumors and enter the bloodstream, serving as vital biomarkers for metastatic progression and therapeutic monitoring. The market is primarily propelled by the rising global cancer burden and the increasing preference for non-invasive liquid biopsy diagnostics. According to the American Cancer Society, an estimated 2,041,910 new cancer cases were projected to be diagnosed in the United States in 2025, underscoring the critical need for effective disease management tools. Additionally, the capability to conduct frequent patient assessments without the risks linked to surgical interventions continues to support industry growth.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.06 Billion
Market Size 2031USD 10.94 Billion
CAGR 2026-20317.57%
Fastest Growing SegmentKits & Reagents
Largest MarketNorth America

However, the market faces a substantial hurdle regarding the lack of standardization in cell isolation technologies. The extremely low abundance of these cells in blood samples makes consistent detection and reproducibility difficult across different platforms. This technical complexity demands expensive instrumentation and specialized processing, resulting in high operational costs that restrict widespread clinical adoption and reimbursement within standard healthcare systems.

Market Driver

Technological advancements in microfluidic and chip-based isolation are transforming the market by resolving the critical bottleneck of low cell abundance in blood samples. These specialized platforms now allow for the label-free capture and harvesting of intact circulating tumor cells, enabling downstream analysis that was previously unachievable with older epithelial marker-dependent methods. The commercial success of these innovations is reflected in the rising adoption of such systems; for instance, according to Alliance News in January 2025, Angle plc reported that its full-year 2024 revenue rose to £2.9 million, driven by the increased deployment of its Parsortix liquid biopsy system in pharma services and clinical settings. This move toward high-sensitivity enrichment tools permits clinicians to perform longitudinal monitoring of metastatic potential with greater precision, directly improving patient management strategies and fueling market growth.

Simultaneously, the increase in public and private funding for oncology research is accelerating the transition of liquid biopsy technologies from academic labs to routine clinical practice. Governments and major health organizations are investing heavily in large-scale studies to validate CTC biomarkers for early detection and treatment selection, acknowledging the urgent need to tackle the growing cancer burden. This clinical urgency was highlighted by the European Commission, which noted in December 2025 that there were approximately 2.7 million new cancer cases estimated across EU Member States in 2024, creating a massive demand for scalable diagnostic solutions. In direct response, substantial financial grants are being awarded to pioneer new methodologies; notably, according to GenomeWeb in May 2025, Oslo University Hospital received a €13.6 million European Union grant specifically to develop and validate liquid biopsy tests for hereditary cancer syndromes.

Market Challenge

The absence of standardization in cell isolation technologies remains a significant impediment to the growth of the Global Circulating Tumor Cells Market. Since circulating tumor cells (CTCs) are present in extremely low abundance within blood samples, detecting them requires complex, highly sensitive instrumentation that often varies in methodology across different manufacturers. This technical inconsistency leads to variable and irreproducible results between laboratories, making it challenging for oncologists to rely on CTCs for critical treatment decisions with the same confidence as established tissue biopsies. Consequently, this variability creates a substantial barrier to regulatory validation and acceptance by the broader medical community.

These technical challenges directly contribute to prohibitive operational costs, further hampering market expansion. The specialized equipment and labor-intensive workflows required to isolate these rare cells drive up the price per test, creating a difficult environment for widespread reimbursement. According to the American Cancer Society, in 2025, an estimated 618,120 cancer deaths were projected to occur in the United States, emphasizing the urgent need for advanced monitoring tools. However, despite this immense clinical burden, healthcare payers and insurance providers remain hesitant to cover expensive, non-standardized CTC assays, thereby limiting their adoption in standard clinical practice and restricting the market's revenue potential.

Market Trends

The integration of Artificial Intelligence for Automated CTC Detection is fundamentally reshaping the market by overcoming the historical challenge of identifying rare tumor cells amidst billions of blood cells. Advanced machine learning algorithms are now being deployed to analyze high-content images, significantly improving detection sensitivity and reducing the variability associated with manual operator bias. This technological leap allows for the standardization of workflows and higher throughput, directly addressing the scalability issues that have hindered clinical adoption. Validating this progress, according to the Journal of Clinical Oncology in May 2024, a study utilizing automated deep learning models for circulating tumor cell analysis demonstrated a detection accuracy of approximately 96.66%, highlighting the potential of AI to deliver the reliability required for routine diagnostic use.

Concurrently, the industry is witnessing a decisive shift from simple enumeration to molecular phenotyping, moving beyond merely counting cells to characterizing their biological properties for precision medicine. Clinicians and researchers are increasingly focused on analyzing the proteomic and genomic profiles of isolated cells to identify specific therapeutic targets and resistance mechanisms, rather than just assessing metastatic burden. This transition towards deeper biological insight is attracting significant investment to support the development of next-generation characterization tools. For instance, according to RareCyte, Inc. in June 2024, the company successfully completed a $20 million financing round specifically aimed at expanding its precision biology platform, which enables the visual retrieval and molecular profiling of single circulating tumor cells.

Key Market Players

  • QIAGEN N.V.
  • Bio-Techne Corp.
  • Precision Medicine Group, LLC
  • Bio-Rad Laboratories, Inc.
  • Natera, Inc.
  • Illumina, Inc.
  • Greiner Bio-One International GmbH
  • Ikonisys Inc.
  • Creative Bioarray
  • Abnova Corporation

Report Scope

In this report, the Global Circulating Tumor Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Circulating Tumor Cells Market, By Product

  • Kits & Reagents
  • Blood Collection Tubes
  • Devices or Systems

Circulating Tumor Cells Market, By Technology

  • CTC Detection & Enrichment Methods
  • CTC Direct Detection Methods
  • CTC Analysis

Circulating Tumor Cells Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Circulating Tumor Cells Market.

Available Customizations:

Global Circulating Tumor Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Circulating Tumor Cells Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Kits & Reagents, Blood Collection Tubes, Devices or Systems)
    • 5.2.2. By Technology (CTC Detection & Enrichment Methods, CTC Direct Detection Methods, CTC Analysis)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Circulating Tumor Cells Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Technology
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Circulating Tumor Cells Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Technology
    • 6.3.2. Canada Circulating Tumor Cells Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Technology
    • 6.3.3. Mexico Circulating Tumor Cells Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Technology

7. Europe Circulating Tumor Cells Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Technology
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Circulating Tumor Cells Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Technology
    • 7.3.2. France Circulating Tumor Cells Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Technology
    • 7.3.3. United Kingdom Circulating Tumor Cells Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Technology
    • 7.3.4. Italy Circulating Tumor Cells Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Technology
    • 7.3.5. Spain Circulating Tumor Cells Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Technology

8. Asia Pacific Circulating Tumor Cells Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Technology
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Circulating Tumor Cells Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Technology
    • 8.3.2. India Circulating Tumor Cells Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Technology
    • 8.3.3. Japan Circulating Tumor Cells Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Technology
    • 8.3.4. South Korea Circulating Tumor Cells Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Technology
    • 8.3.5. Australia Circulating Tumor Cells Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Technology

9. Middle East & Africa Circulating Tumor Cells Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Technology
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Circulating Tumor Cells Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Technology
    • 9.3.2. UAE Circulating Tumor Cells Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Technology
    • 9.3.3. South Africa Circulating Tumor Cells Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Technology

10. South America Circulating Tumor Cells Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Technology
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Circulating Tumor Cells Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Technology
    • 10.3.2. Colombia Circulating Tumor Cells Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Technology
    • 10.3.3. Argentina Circulating Tumor Cells Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Technology

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Circulating Tumor Cells Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. QIAGEN N.V.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bio-Techne Corp.
  • 15.3. Precision Medicine Group, LLC
  • 15.4. Bio-Rad Laboratories, Inc.
  • 15.5. Natera, Inc.
  • 15.6. Illumina, Inc.
  • 15.7. Greiner Bio-One International GmbH
  • 15.8. Ikonisys Inc.
  • 15.9. Creative Bioarray
  • 15.10. Abnova Corporation

16. Strategic Recommendations

17. About Us & Disclaimer